Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

Semaglutide: First Global Approval

(2018) Sohita Dhillon   DRUGS

Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus

(2018) Yuanmei Zhu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial–approved membrane fusion inhibitor

(2018) Danwei Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Design of Novel HIV-1/2 Fusion Inhibitors with Efficient Therapeutic Efficacy in Rhesus Monkey Models

(2018) Huihui Chong et al.   JOURNAL OF VIROLOGY

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

(2018) Xiujuan Zhang et al.   Frontiers in Cellular and Infection Microbiology

Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

(2018) Huihui Chong et al.   JOURNAL OF VIROLOGY

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition

(2017) Xiaohui Ding et al.   JOURNAL OF VIROLOGY

A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro , Ex Vivo , and In Vivo Antiviral Activity

(2017) Huihui Chong et al.   JOURNAL OF VIROLOGY

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Development of potent and long-acting HIV-1 fusion inhibitors

(2016) Huihui Chong et al.   AIDS

A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

(2016) Shengwen Xiong et al.   JOURNAL OF VIROLOGY

Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket

(2015) Huihui Chong et al.   AIDS

Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41

(2015) Zonglin Qiu et al.   AIDS

Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket

(2015) Yang Su et al.   JOURNAL OF VIROLOGY

Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket

(2015) Yang Su et al.   JOURNAL OF VIROLOGY

Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure

(2014) M. T. Augusto et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance

(2014) Huihui Chong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Synthesized Peptide Inhibitors of HIV-1 gp41-dependent Membrane Fusion

(2013) Yuxian He   CURRENT PHARMACEUTICAL DESIGN

Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1

(2012) Avraham Ashkenazi et al.   FASEB JOURNAL

Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1

(2012) Huihui Chong et al.   FASEB JOURNAL

Discovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621–652

(2012) Huihui Chong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide

(2012) Xue Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M

(2012) Xue Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors

(2012) Huihui Chong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function

(2011) D. Eggink et al.   JOURNAL OF VIROLOGY

Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain

(2010) Yael Wexler-Cohen et al.   FASEB JOURNAL

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

(2010) X. Wu et al.   SCIENCE

HIV-1 Entry, Inhibitors, and Resistance

(2010) Michael A. Lobritz et al.   Viruses-Basel

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

(2009) P. Ingallinella et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Membrane-Anchored HIV-1 N-Heptad Repeat Peptides Are Highly Potent Cell Fusion Inhibitors via an Altered Mode of Action

(2009) Yael Wexler-Cohen et al.   PLoS Pathogens

Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition

(2008) Y. He et al.   JOURNAL OF VIROLOGY

Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors

(2008) Y. He et al.   JOURNAL OF VIROLOGY

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

(2008) Y. He et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA